Comparative analysis of adjuvant therapy for stage III BRAF‐mut melanoma: A real‐world retrospective study from single center in China

BACKGROUND: BRAF V600 mutation is the most common oncogenic alternation in melanoma and is visible in around 50% of cutaneous and 10%–15% of acral or mucosal subtypes. Currently, immunotherapy with anti‐PD‐1 blockade and dual‐targeted therapy with Dabrafenib plus trametinib (D + T) target therapy ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Jingqin, Sun, Wei, Hu, Tu, Wang, Chunmeng, Yan, Wangjun, Luo, Zhiguo, Liu, Xin, Xu, Yu, Chen, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242313/
https://www.ncbi.nlm.nih.gov/pubmed/37016119
http://dx.doi.org/10.1002/cam4.5866

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242313/
https://www.ncbi.nlm.nih.gov/pubmed/37016119
http://dx.doi.org/10.1002/cam4.5866

Ejemplares similares